| Loteprednol-etabonate | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa01522 | Endocrine resistance | 2.16E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04012 | ErbB signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04014 | Ras signaling pathway | 3.65E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04015 | Rap1 signaling pathway | 2.99E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04022 | cGMP-PKG signaling pathway | 3.15E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04024 | cAMP signaling pathway | 2.49E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04062 | Chemokine signaling pathway | 3.98E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04071 | Sphingolipid signaling pathway | 2.16E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04072 | Phospholipase D signaling pathway | 2.82E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04140 | Autophagy - animal | 2.82E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04150 | mTOR signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04210 | Apoptosis | 2.16E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04218 | Cellular senescence | 2.49E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04270 | Vascular smooth muscle contraction | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04360 | Axon guidance | 2.49E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04370 | VEGF signaling pathway | 8.29E-03 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04371 | Apelin signaling pathway | 2.65E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04510 | Focal adhesion | 3.48E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04540 | Gap junction | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04613 | Neutrophil extracellular trap formation | 2.65E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04625 | C-type lectin receptor signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04630 | JAK-STAT signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04650 | Natural killer cell mediated cytotoxicity | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04660 | T cell receptor signaling pathway | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04662 | B cell receptor signaling pathway | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04664 | Fc epsilon RI signaling pathway | 1.16E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04666 | Fc gamma R-mediated phagocytosis | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04720 | Long-term potentiation | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04722 | Neurotrophin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04726 | Serotonergic synapse | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04730 | Long-term depression | 1.16E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04810 | Regulation of actin cytoskeleton | 3.81E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04910 | Insulin signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04912 | GnRH signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04914 | Progesterone-mediated oocyte maturation | 2.16E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04915 | Estrogen signaling pathway | 2.99E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04916 | Melanogenesis | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04917 | Prolactin signaling pathway | 6.63E-03 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04919 | Thyroid hormone signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04921 | Oxytocin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04926 | Relaxin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04928 | Parathyroid hormone synthesis, secretion and action | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04929 | GnRH secretion | 4.98E-03 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa04935 | Growth hormone synthesis, secretion and action | 2.16E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05034 | Alcoholism | 2.49E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05132 | Salmonella infection | 4.98E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05152 | Tuberculosis | 3.98E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05160 | Hepatitis C | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05161 | Hepatitis B | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05163 | Human cytomegalovirus infection | 4.98E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05164 | Influenza A | 3.65E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 3.15E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05170 | Human immunodeficiency virus 1 infection | 3.48E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05205 | Proteoglycans in cancer | 3.48E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05206 | MicroRNAs in cancer | 3.15E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05210 | Colorectal cancer | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05211 | Renal cell carcinoma | 1.16E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05212 | Pancreatic cancer | 1.16E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05213 | Endometrial cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05214 | Glioma | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05218 | Melanoma | 6.63E-03 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05219 | Bladder cancer | 4.98E-03 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05220 | Chronic myeloid leukemia | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05221 | Acute myeloid leukemia | 8.29E-03 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05223 | Non-small cell lung cancer | 6.63E-03 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05224 | Breast cancer | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05226 | Gastric cancer | 8.29E-03 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05230 | Central carbon metabolism in cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05231 | Choline metabolism in cancer | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Loteprednol-etabonate | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.66E-02 | 1 | P04049 | RAF1 | More | |
